• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Calithera Biosciences Inc. (Amendment)

    2/9/23 4:01:25 PM ET
    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CALA alert in real time by email
    SC 13G/A 1 calaa6_20923.htm PRIMECAP MANAGEMENT CO/CA/ calaa6_20923.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 6)*
    Calithera Biosciences, Inc.
    (Name of Issuer)
    COM
    (Title of Class of Securities)
    13089P507
    (CUSIP Number)
    January 31, 2023
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 13089P507
           
    1
    NAME OF REPORTING PERSON
    PRIMECAP Management Company
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    95-3868081
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    199,963
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    199,963
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    199,963
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    4.11%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: 13089P507
    ITEM 1(a). NAME OF ISSUER:
    Calithera Biosciences, Inc.
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    343 Oyster Point Blvd, Suite 200, South San Francisco, CA 94080
    ITEM 2(a). NAME OF PERSON FILING:
    PRIMECAP Management Company
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105
    ITEM 2(c). CITIZENSHIP:
    U.S.A.
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    COM
    ITEM 2(e). CUSIP NUMBER:
    13089P507
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    199,963
    (b) Percent of class:
    4.11%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    199,963
    (ii) shared power to vote or to direct the vote:
    0
    (iii) sole power to dispose or direct the disposition of:
    199,963
    (iv) shared power to dispose or to direct the disposition of:
    0
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    Not Applicable
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    Not Applicable
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    Not Applicable
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    Not Applicable
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 13089P507
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 09 2023
    PRIMECAP Management Company
    By:
    /s/ Julietta Martikyan
    Name:
    Julietta Martikyan
    Title:
    Director of Compliance and Administration
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $CALA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CALA

    DatePrice TargetRatingAnalyst
    1/31/2022$4.00Buy
    Ladenburg Thalmann
    1/20/2022$1.00 → $3.00Market Perform → Outperform
    SVB Leerink
    11/8/2021Buy → Neutral
    HC Wainwright & Co.
    11/5/2021Outperform → Market Perform
    William Blair
    More analyst ratings

    $CALA
    Financials

    Live finance-specific insights

    See more
    • Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update

      SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the third quarter ended September 30, 2022. "Earlier in the fourth quarter, we were very pleased to announce that we received FDA Fast Track designation for sapanisertib. This designation facilitates more frequent communication with the Agency, as well as a number of other benefits that could support our efforts to bring sapanisertib to patients in this area of high unmet need more quickly," said Susan Molineaux, PhD, president and chief executive officer of Calithera. "Today we a

      11/14/22 4:05:00 PM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

      SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company's third quarter 2022 financial results will be released on Monday, November 14, 2022. Company management will host a conference call on Monday, November 14, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. Participants who wish to join the conference call by telephone can use this link to register and receive the dial-in numbers and unique PIN to access the call. The conference call registration and live audio webcast c

      11/8/22 4:30:00 PM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

      SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022. "We continue to deliver on our commitment to efficiently advance our clinical programs, successfully initiating two new clinical trials and sharing program updates at two important medical conferences," said Susan Molineaux, PhD, president and chief executive officer of Calithera. "We look forward to sharing data from the ongoing mivavotinib and sapanisertib phase 2 trials by the first quarter of 2023, as well as providing an update on the p

      8/15/22 4:05:00 PM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Takeda Pharmaceutical Co Ltd

      4 - Calithera Biosciences, Inc. (0001496671) (Issuer)

      5/26/23 7:08:15 AM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Pakianathan Deepika sold $46,810 worth of shares (121,333 units at $0.39)

      4 - Calithera Biosciences, Inc. (0001496671) (Issuer)

      1/31/23 7:04:07 PM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Sjogren Eric covered exercise/tax liability with 279 shares, decreasing direct ownership by 3% to 8,467 units (for withholding tax)

      4 - Calithera Biosciences, Inc. (0001496671) (Issuer)

      1/25/23 4:00:25 PM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

      SOUTH SAN FRANCISCO, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: "CALA"). Calithera Biosciences, Inc. (the "Company") announced that it was unable to achieve a quorum of stockholders at its special meeting of stockholders scheduled to be held on June 29, 2023 (the "Special Meeting"), for the purpose of approving the Company's Plan of Complete Liquidation and Dissolution. In January 2023, the Company announced its intention to commence an orderly wind down of the Company's business and operations. After consulting with its proxy solicitation advisors, the Company concluded that further attempts to solicit proxies for the Special Meeting would in all likelihoo

      6/29/23 4:01:07 PM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

      SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC:CALA) (the "Company") announced that it intends to hold a special meeting of stockholders on or about June 29, 2023 (the "Special Meeting"),  for the purpose of approving the Company's Plan of Complete Liquidation and Dissolution (the "Plan of Dissolution").  In January 2023, the Company announced its intention to commence an orderly wind down of the Company's business and operations.   The Company continues to expect that its existing capital resources together with the net proceeds from the sale of its assets will enable it to meet its remaining liabilities and obligations with sufficient reser

      5/19/23 4:01:00 PM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

      SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic alternatives, that it is in the best interests of its shareholders to dissolve the Company and liquidate its assets, following an orderly wind down of the company's operations. In order to reduce costs and in connection with the planned dissolution, Calithera is discontinuing all clinical development programs and reducing its workforce, including the termination of most employees by the end of the first quarter. "The Board of Directors and management devoted substantial t

      1/9/23 8:00:26 AM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on Calithera Biosciences with a new price target

      Ladenburg Thalmann initiated coverage of Calithera Biosciences with a rating of Buy and set a new price target of $4.00

      1/31/22 7:56:32 AM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Calithera Biosciences upgraded by SVB Leerink with a new price target

      SVB Leerink upgraded Calithera Biosciences from Market Perform to Outperform and set a new price target of $3.00 from $1.00 previously

      1/20/22 6:11:04 AM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Calithera Biosciences downgraded by HC Wainwright & Co.

      HC Wainwright & Co. downgraded Calithera Biosciences from Buy to Neutral

      11/8/21 6:07:15 AM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Calithera Biosciences Inc. (Amendment)

      SC 13D/A - Calithera Biosciences, Inc. (0001496671) (Subject)

      5/26/23 7:08:52 AM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Calithera Biosciences Inc. (Amendment)

      SC 13G/A - Calithera Biosciences, Inc. (0001496671) (Subject)

      2/14/23 11:48:11 AM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Calithera Biosciences Inc. (Amendment)

      SC 13G/A - Calithera Biosciences, Inc. (0001496671) (Subject)

      2/14/23 8:02:36 AM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALA
    Leadership Updates

    Live Leadership Updates

    See more
    • Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      SOUTH SAN FRANCISCO, Calif., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 50,000 shares of Calithera’s common stock, at a per share exercise price of $4.91, the closing trading price on December 31, 2020. One-fourth of the option vests in December 2021, and the balance of the option vests in a series of thirty-six successive equ

      12/31/20 4:55:30 PM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALA
    SEC Filings

    See more
    • SEC Form DEFM14A filed by Calithera Biosciences Inc.

      DEFM14A - Calithera Biosciences, Inc. (0001496671) (Filer)

      6/5/23 5:16:29 PM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PREM14A filed by Calithera Biosciences Inc.

      PREM14A - Calithera Biosciences, Inc. (0001496671) (Filer)

      5/26/23 4:26:52 PM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Calithera Biosciences Inc.

      DEFA14A - Calithera Biosciences, Inc. (0001496671) (Filer)

      5/19/23 8:50:55 PM ET
      $CALA
      Biotechnology: Pharmaceutical Preparations
      Health Care